IP Library › Granted Patent US 10,919,966
Granted Patent B2
US 10,919,966 · App. 16/321,412 · Granted Feb 16, 2021

Antibody to programmed death-ligand 1 (PD-L1) and use thereof

Inventors: Jae Eun Park (Daejeon, KR); Soo A Choi (Jeollabuk-do, KR); Jisu Lee (Sejong, KR); Hyun Mi Lee (Daejeon, KR); Si Hyung Lee (Daejeon, KR); Gi Sun Baek (Daejeon, KR); Yeung Chul Kim (Daejeon, KR); Bum-chan Park (Daejeon, KR); Jung Chae Lim (Daejeon, KR); Young-Gyu Cho (Daejeon, KR); Young Woo Park (Daejeon, KR)
Assignee: Y-BIOLOGICS INC.
C07K16/2827C07K2317/565C07K2317/567C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,919,966
App. No.
16/321,412
Granted
Feb 16, 2021
Kind
B2
Abstract

Disclosed are an antibody to human programmed cell death-ligand 1 (PD-L1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer or infectious diseases containing the same.

Claims (53)

1. An antibody binding to PD-L1 or an antigen-binding fragment thereof, comprising:

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 1, the heavy chain CDR2 of SEQ ID NO: 8 and the heavy chain CDR3 of SEQ ID NO: 16, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 88, the light chain CDR2 of SEQ ID NO: 103 and the light chain CDR3 of SEQ ID NO: 120;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 121;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 18, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 90, the light chain CDR2 of SEQ ID NO: 105 and the light chain CDR3 of SEQ ID NO: 122;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 3, the heavy chain CDR2 of SEQ ID NO: 10 and the heavy chain CDR3 of SEQ ID NO: 19, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 91, the light chain CDR2 of SEQ ID NO: 106 and the light chain CDR3 of SEQ ID NO: 123;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 4, the heavy chain CDR2 of SEQ ID NO: 11 and the heavy chain CDR3 of SEQ ID NO: 20, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 107 and the light chain CDR3 of SEQ ID NO: 124;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 5, the heavy chain CDR2 of SEQ ID NO: 12 and the heavy chain CDR3 of SEQ ID NO: 21, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 92, the light chain CDR2 of SEQ ID NO: 108 and the light chain CDR3 of SEQ ID NO: 122;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 6, the heavy chain CDR2 of SEQ ID NO: 13 and the heavy chain CDR3 of SEQ ID NO: 22, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 93, the light chain CDR2 of SEQ ID NO: 109 and the light chain CDR3 of SEQ ID NO: 125;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 23, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 94, the light chain CDR2 of SEQ ID NO: 110 and the light chain CDR3 of SEQ ID NO: 126;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 7, the heavy chain CDR2 of SEQ ID NO: 14 and the heavy chain CDR3 of SEQ ID NO: 24, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 95, the light chain CDR2 of SEQ ID NO: 111 and the light chain CDR3 of SEQ ID NO: 127;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 15 and the heavy chain CDR3 of SEQ ID NO: 25, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 96, the light chain CDR2 of SEQ ID NO: 112 and the light chain CDR3 of SEQ ID NO: 128;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 108 and the light chain CDR3 of SEQ ID NO: 129;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105 and the light chain CDR3 of SEQ ID NO: 130;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 113 and the light chain CDR3 of SEQ ID NO: 131;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 97, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 132;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 133;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 97, the light chain CDR2 of SEQ ID NO: 114 and the light chain CDR3 of SEQ ID NO: 134;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 92, the light chain CDR2 of SEQ ID NO: 115 and the light chain CDR3 of SEQ ID NO: 135;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 98, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 130;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 116 and the light chain CDR3 of SEQ ID NO: 121;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 108 and the light chain CDR3 of SEQ ID NO: 136;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 99, the light chain CDR2 of SEQ ID NO: 105 and the light chain CDR3 of SEQ ID NO: 137;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 117 and the light chain CDR3 of SEQ ID NO: 138;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 118 and the light chain CDR3 of SEQ ID NO: 133;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 119 and the light chain CDR3 of SEQ ID NO: 139;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 100, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 140;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 108 and the light chain CDR3 of SEQ ID NO: 141;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105 and the light chain CDR3 of SEQ ID NO: 139;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 142;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105 and the light chain CDR3 of SEQ ID NO: 143;

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 101, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 141; or

a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 102, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 144.

2. The antibody or an antigen-binding fragment thereof according to claim 1 , comprising:

a heavy chain variable region FR1 selected from the group consisting of SEQ ID NOS: 26 to 34;

a heavy chain variable region FR2 selected from the group consisting of SEQ ID NOS: 35 to 41;

a heavy chain variable region FR3 selected from the group consisting of SEQ ID NOS: 42 to 49; or

a heavy chain variable region FR4 selected from the group consisting of SEQ ID NOS: 50 to 54.

3. The antibody or an antigen-binding fragment thereof according to claim 1 , comprising:

a light chain variable region FR1 selected from the group consisting of SEQ ID NOS: 145 to 163;

a light chain variable region FR2 selected from the group consisting of SEQ ID NOS: 164 to 184;

a light chain variable region FR3 selected from the group consisting of SEQ ID NOS: 185 to 210; or

a light chain variable region FR4 selected from the group consisting of SEQ ID NOS: 211 to 216.

4. The antibody or an antigen-binding fragment thereof according to claim 1 , comprising:

a heavy chain variable region comprising a sequence selected from the group consisting of sequences as set forth in SEQ ID NOS: 57 to 87.

5. The antibody or an antigen-binding fragment thereof according to claim 1 , comprising:

a light chain variable region comprising a sequence selected from the group consisting of sequences as set forth in SEQ ID NOS: 217 to 247.

6. A nucleic acid encoding the antibody or an antigen-binding fragment thereof according to claim 1 .

7. An expression vector comprising the nucleic acid according to claim 6 .

8. A cell transformed with the expression vector according to claim 7 .

9. A method for producing an antibody binding to PD-L1 or an antigen-binding fragment thereof, comprising:

(a) culturing the cell according to claim 8 ; and

(b) recovering the antibody or antigen-binding fragment thereof from the cultured cell.

10. A composition for preventing or treating cancer or infectious diseases which expresses PD-L1 comprising, as an active ingredient, the antibody or an antigen-binding fragment thereof according to claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2019
From: PARK, JAE EUN; CHOI, SOO A; LEE, JISU; LEE, HYUN MI; LEE, SI HYUNG; BAEK, GI SUN; KIM, YEUNG CHUL; PARK, BUM-CHAN; LIM, JUNG CHAE; CHO, YOUNG-GYU; PARK, YOUNG WOO
To: Y-BIOLOGICS INC.
Reel/Frame 048614/0297 →
Priority Claims (2)
KR 10-2016-0100211 · Aug 5, 2016 · national
KR 10-2017-0099673 · Aug 7, 2017 · national
Continuity (1)
Related Publication 20190322750A1 · Oct 24, 2019